Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.37 |
| ▸ | HTR1F | P30939 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KHK | P50053 | 4/20 | 0.34 |
| ▸ | SCD | O00767 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13432160 | 0.84 | KMO (0.43) | KMOCHRM2CHRM1CHRM3HTR1A | |
| SCHEMBL21251097 | 0.82 | PIK3CD (0.43) | KMOCHRM2CHRM1CHRM3HTR1A | |
| SCHEMBL20116278 | 0.82 | CHRM2 (0.43) | KMOCHRM2CHRM1CHRM3HTR1A | |
| SCHEMBL17678157 | 0.81 | KMO (0.41) | KMOCHRM2CHRM1CHRM3HTR1A | |
| SCHEMBL31389731 | 0.81 | TERT (0.37) | HTR1AHTR1BHTR1FSCDLRRK2 | |
| SCHEMBL22357771 | 0.81 | HSD11B1 (0.41) | HTR1AHTR1BHTR1FSCDCYP11B2 | |
| SCHEMBL20116574 | 0.80 | PDE1B (0.40) | KMOCHRM2CHRM1CHRM3HTR1A | |
| SCHEMBL20116283 | 0.80 | KHK (0.42) | KMOCHRM2CHRM1CHRM3HTR1A | |
| SCHEMBL20116866 | 0.80 | KMO (0.43) | KMOCHRM2CHRM1CHRM3HTR1A | |
| SCHEMBL20117063 | 0.79 | KMO (0.43) | KMOCHRM2CHRM1CHRM3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-20 | — | — | US | disclosed |
| WO-2019018795-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018081167-A1 | COMPOUNDS AND USES THEREOF | YUMANITY THERAPEUTICS (US) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | KMO 1174/4885CHRM2 1129/4885CHRM1 1838/4885 |
| US-20200262828-A1 | COMPOUNDS AND USES THEREOF | NLN, ACHE, CLN6 | KMO 1174/4885CHRM2 1129/4885CHRM1 1838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.